Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers

Journal of Clinical Pharmacy and Therapeutics

Volumn 33, Issue 5, 2008, Pages 567-573

  Jin, S K ^a,c   Chung, H J ^c   Chung, M W ^c   Kim, J I ^c   Kang, J H ^d   Woo, S W ^c   Bang, S ^c   Lee, S H ^e   Lee, H J ^a   Roh, J ^b  

^a Ewha Womans University   (South Korea)

^b Hanyang University Medical Center   (South Korea)

^c Korea Food and Drug Administration   (South Korea)

^d Inha University School of Medicine   (South Korea)

^e College of Medicine   (South Korea)

Author keywords

CYP2D6; Korean; Metoprolol; Pharmacokinetics

Indexed keywords

ALPHA HYDROXYMETOPROLOL; CYTOCHROME P450 2D6; METOPROLOL; ALPHA-HYDROXYMETOPROLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DRUG DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACOGENETICS; SOUTH KOREA; ASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENETICS; HALF LIFE TIME; KOREA; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADRENERGIC BETA-ANTAGONISTS; ADULT; ALLELES; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2D6; FEMALE; HALF-LIFE; HUMANS; KOREA; MALE; METOPROLOL; PHARMACOGENETICS; POLYMORPHISM, GENETIC; YOUNG ADULT;

EID: 52049120158     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2008.00945.x     Document Type: Article

References (43)

1. Gonzalez FJ (1988) The molecular biology of cytochrome P450s. Pharmacoogical Reviews, 40, 243 288.
2. Bertilsson L, Dahl ML (1996) Polymorphic drug oxidation: relevance to the treatment of psychiatric disorders. CNS Drugs, 5, 200 223.
3. Dorne JLCM, Walton K, Slob W, Renwick AG (2002) Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate? Food and Chemical Toxicology, 40, 1633 1656.
4. Nagata K, Yamazoe Y (2002) Genetic polymorphism of human cytochrome P450 involved in drug metabolism. Drug Metabolism and Pharmacokinetics, 17, 167 189.
5. Nelson DR, Koymans L, Kamataki T et al. (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 6, 1 42.
6. Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. The Pharmacogenomics Journal, 5, 6 13.
7. Zanger UM, Raimundo S, Eichelbaum M (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedeberg's Archives of Pharmacology, 369, 23 37.
8. Ingelman-Sundberg M (2001) Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. Journal of Internal Medicine, 250, 186 200.
9. Bertilsson L, Lou YQ, Du YL et al. (1992) Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clinical Pharmacology and Therapeutics, 51, 388 397.
10. Sohn DR, Shin SG, Park CW, Kusaka M, Chiba K, Ishizaki T (1991) Metoprolol oxidation polymorphism in an Korean population comparison with native Japanese and Chinese populations. British Journal of Clinical Pharmacology, 32, 504 507.
11. Bertilsson L, Dahl ML, Dalén P, Al-Shurbaji A (2002) Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. British Journal of Clinical Pharmacology, 53, 111 122.
12. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M (1994) Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Molecular Pharmacology, 46, 452 459.
13. Roh HK, Dahl ML, Johansson I, Ingelman-Sundberg M, Cha YN, Bertilsson L (1996) Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics, 6, 441 447.
14. Yue QY, Zhong ZH, Tybring G, Dalén P, Dahl ML, Bertilsson L, Sjöqvist F (1998) Pharmacokinetics of nortriptyline and its 10-hydroxymetabolite in Chinese subjects of different CYP2D6 genotypes. Clinical Pharmacology and Therapeutics, 64, 384 390.
15. Olsson G, Rehnqvist N, Sjögren A, Erhardt L, Lundman T (1985) Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. Journal of the American College of Cardiology, 5, 1428 1437.
16. Wikstrand J, Warnold I, Tuomilehto J et al. (1991) Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY study. Hypertension, 17, 574 588.
17. MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet, 353, 2001 2007.
18. Benfield P, Clissold SP, Brogden RN (1986) Metoprolol: an updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders. Drugs, 31, 376 429.
19. Li F, Cooper SF, Côté M (1995) Determination of the enantiomers of metoprolol and its major acidic metabolite in human urine by high-performance liquid chromatography with fluorescence detection. Journal of Chromatography B, 668, 67 75.
20. Murthy SS, Shetty HU, Nelson WL, Jackson PR, Lennard MS (1990) Enantioselective and diastereoselective aspects of the oxidative metabolism of metoprolol. Biochemical Pharmacology, 40, 1637 1644.
21. Hamelin BA, Bouayad A, Méthot J et al. (2000) Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity. Clinical Pharmacology and Therapeutics, 67, 466 477.
22. Lennard MS, Tucker GT, Silas JH, Woods HF (1986) Debrisoquin polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. Xenobiotica, 16, 435 447.
23. McGourty JC, Silas JH, Lennard MS, Tucker GT, Woods HF (1985) Metoprolol metabolism and debrisoquin oxidation polymorphism-population and family studies. British Journal of Clinical Pharmacology, 20, 555 566.
24. Huang JD, Chuang SK, Cheng CL, Lai ML (1999) Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes. Clinical Pharmacology and Therapeutics, 65, 402 407.
25. Taguchi M, Nozawa T, Kameyama T, Inoue H, Takesono C, Mizukami A, Hashimoto Y (2003) Effect of CYP2D6*10 on pharmacokinetic variability of routinely administered metoprolol in middle-aged and elderly Japanese patients. European Journal of Clinical Pharmacology, 59, 385 388.
26. Sambrook J, Russell DW (2001) Molecular cloning: a laboratory manual. New York : Cold Spring Harbor Laboratory Press.
27. Hersberger M, Mrti-Jaun J, Rentsch K, Hänseler E (2000) Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clinical Chemistry, 46, 1072 1077.
28. Rau T, Heide R, Bergmann K, Wuttke H, Werner U, Feifel N, Eschenhagen T (2002) Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics, 12, 465 472.
29. Mistry B, Leslie J, Eddington NE (1998) A sensitive assay of metoprolol and its major metabolite α-hydroxymetoprolol in human plasma and determination of dextromethorphan and its metabolite dextrorphan in urine with high performance liquid chromatography and fluorometric detection. Journal of Pharmaceutical and Biomedical Analysis, 16, 1041 1049.
30. Shah VP, Midha KK, Dighe S et al. (1991) Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. European Journal of Drug Metabolism and Pharmacokinetics, 16, 249 255.
31. Rendic S, Di Carlo FJ (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metabolism and Reviews, 29, 413 580.
32. Zanger UM, Fischer J, Raimundo S, Stüven T, Evert BO, Schwab M, Eichelbaum M (2001) Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics, 11, 573 585.
33. Shimada T, Tsumura F, Yamazaki H, Guengerich FP, Inoue K (2001) Characterization of (±)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6. Pharmacogenetics, 11, 143 156.
34. Sachse C, Brockmöller J, Hildebrand M, Müller K, Roots I (1998) Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizers of debrisoquine. Pharmacogenetics, 8, 181 185.
35. McElroy S, Sachse C, Brockmoller J et al. (2000) CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting. AAPS PharmSci, 2, E33.
36. Kim K, Johnson JA, Derendorf H (2004) Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. Journal of Clinical Pharmacology, 44, 1083 1105.
37. Roh HK, Kim CE, Chung WG, Park CS, Svensson JO, Bertilsson L (2001) Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. European Journal of Clinical Pharmacology, 57, 671 675.
38. Fukuda T, Yamamoto I, Nishida Y, Zhou Q, Ohno M, Takada K, Azuma J (1999) Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. British Journal of Clinical Pharmacology, 47, 450 453.
39. Brockmöller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Müller-Oerlinghausen B, Roots I. (2002) The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clinical Pharmacology and Therapeutics, 72, 438 452.
40. Mizutani T (2003) PM frequencies of major CYPs in Asians and Caucasians. Drug Metabolism and Reviews, 35, 99 106.
41. Kirchheiner J, Heesch C, Bauer S et al. (2004) Impact of the ultrarapid metabolizer genotype of cytochrome P450 2D6 on metoprolol pharmacokinetics and pharmacodynamics. Clinical Pharmacology and Therapeutics, 76, 302 312.
42. Ismail R, Teh LK (2006) The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients. Journal of Clinical Pharmacy and Therapeutics, 31, 99 109.
43. Hägg S, Spigset O, Dahqvist R (2001) Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. British Journal of Clinical Pharmacology, 51, 169 173.